OLANZAPINE        FEWER DROP-OUTS THAN LITHIUM 
Reduced relapse rate
Longer time to relapse
At least as effective as lithium
OFC in bipolar depression
No treatment-emergent mania
Improvements in HR-Qol
Fewer drop-outs than lithium
Supporting data
No QTc prolongation
Usage
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Fewer drop-outs than lithium

More patients remain on olanzapine therapy compared with lithium in the maintenance of bipolar disorder

During a head-to-head maintenance trial of olanzapine versus lithium, significant differences were observed favoring olanzapine over lithium when assesing time to discontinuation for any reason and overall completion rate (presented as a poster at scientific meetings including the International Congress of Biological Psychiatry, Sydney, Australia, 2004).

GSK counterclaim:

Weight gain has been observed with olanzapine treatment in every clinical trial presented to date. Depression and somnolence are consistently among the most frequently observed side effects with olanzapine maintenance treatment (Support data 1 and 2).



  
 Supporting trials
- Olanzapine vs lithium for prevention of relapse
- Olanzapine for maintenance of bipolar disorder

 
home help sitemap acronyms help sitemap home